
NIKA PHARMACEUTICALS, INC
90
Recent news coverage includes industry and market developments relevant to pharmaceuticals and biotech sectors but does not directly mention NIKA Pharmaceuticals.
- Chevron is increasing production in Venezuela, reflecting broader energy sector dynamics that may indirectly affect pharmaceutical markets [N1].
- Mirum Pharmaceuticals announced positive Phase 3 trial results for Brelovitug, highlighting ongoing clinical advancements in the pharmaceutical industry [N2].
- CMC announced CFO retirement and successor appointment, indicating leadership changes in related biotech firms [N3].
- Cotton and soybeans markets show gains, reflecting commodity trends that may influence supply chains [N4][N5].
- Discussions on Palantir's stock and Cathie Wood's ARK investments illustrate broader market interest in technology and biotech sectors [N6][N8].
NIKA Pharmaceuticals, Inc. operates in the pharmaceutical and dietary supplement industry with a focus on production and distribution of specialized products. The company has entered into multiple exclusive rights agreements for drugs and supplements, including Thymus Nuclear Glycoprotein (TNG) and several dietary supplements. It collaborates with partners for development, production, and distribution, sharing costs and profits equally in some agreements. NIKA holds an 80% controlling interest in Nika Europe, Ltd., which is preparing to build a pharmaceutical manufacturing facility. The company is publicly traded on the OTCQB market under the ticker NIKA. It qualifies as an emerging growth company and benefits from certain regulatory exemptions. Financially, the company reported no revenue for fiscal year 2024 and a net loss for the first nine months of 2026, with liquidity challenges indicated by a low current ratio.
NIKA Pharmaceuticals, Inc. is a Colorado-incorporated company focusing on pharmaceutical and dietary supplement production and distribution through exclusive rights agreements and joint ventures. The company holds exclusive rights to produce and distribute Thymus Nuclear Glycoprotein (TNG) and several dietary supplements, with partnerships including VITAL FE, MICAR 11 LTD, Immunotech Laboratories BG, Ltd., and Nika BioTechnology, Inc. It has a controlling interest in Nika Europe, Ltd., which is developing pharmaceutical manufacturing capacity. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. As of September 30, 2026, the company reported a net loss of $13.023 million and a very low liquidity position with current liabilities far exceeding current assets. The company operates with a small executive team and has not yet adopted formal insider trading policies.
NIKA Pharmaceuticals has secured long-term exclusive rights to manufacture and distribute unique pharmaceutical products and dietary supplements, supported by intellectual property and clinical trial history. Its strategic partnerships and joint ventures enable shared development costs and expanded market access, including a controlling stake in a European pharmaceutical manufacturing entity. These factors provide a foundation for potential growth in product offerings and geographic reach as the company develops its manufacturing capabilities and commercializes its portfolio.
NIKA Pharmaceuticals faces significant financial challenges, including a net loss of $13 million over nine months and a very low liquidity position with current liabilities vastly exceeding current assets. The company operates with a small executive team and has not yet implemented formal insider trading policies. Its emerging growth company status limits disclosure and regulatory requirements, which may affect transparency. The lack of reported revenue and reliance on partnerships and joint ventures introduce execution risks. The pharmaceutical manufacturing facility is still in preparation, indicating potential delays or capital needs.
NIKA Pharmaceuticals' moat is primarily based on exclusive rights agreements and intellectual property licenses for specialized pharmaceutical products and dietary supplements. Its partnerships with technology holders and joint ventures provide access to patented drug platforms and manufacturing capabilities. The controlling interest in Nika Europe, Ltd. and plans for a dedicated pharmaceutical factory contribute to its production capacity and market reach. However, the company's small scale, emerging growth status, and limited financial resources present challenges to establishing a durable competitive advantage.
• Financial Liquidity Risk: The company has a very low current ratio of 0.02 as of September 30, 2026, indicating that current liabilities far exceed current assets, which may impact its ability to meet short-term obligations.
• Operational Execution Risk: NIKA relies on partnerships and joint ventures for development, production, and distribution, which may introduce coordination and execution challenges.
• Regulatory and Compliance Risk: As an emerging growth company, NIKA benefits from reduced disclosure requirements but may face increased scrutiny as it grows and must comply with more stringent regulations.
• Limited Management and Governance: The company operates with only two executive officers and has not adopted formal insider trading policies, which may affect governance and risk management.
Business trends: The company is focused on developing and distributing specialized pharmaceutical products and dietary supplements through exclusive agreements and joint ventures.
Execution milestones: Key milestones include the merger with Nika BioTechnology, controlling interest in Nika Europe, and preparation of pharmaceutical manufacturing facilities.
Key risks: Financial liquidity constraints, reliance on partnerships for execution, limited management structure, and regulatory compliance challenges.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- NIKA Pharmaceuticals, Inc. is incorporated in Colorado since June 6, 2000.
- The company changed its business focus following a stock purchase agreement.
- On April 7, 2022, NIKA signed an exclusive rights agreement with VITAL FE Joint Stock Company for 15 years to produce and distribute Thymus Nuclear Glycoprotein (TNG), a drug with Phase III clinical trial history related to HIV treatment.
- On the same date, NIKA signed a 15-year exclusive rights agreement with MICAR 11 LTD for two dietary supplements: Carotilen and Physiolong, which have specific health benefits related to metabolism, immune system, and recovery.
- On August 1, 2022, NIKA signed a joint business agreement with Immunotech Laboratories BG, Ltd. to register, produce, and distribute medicinal products based on the Inactivated Pepsin Fraction platform with multiple U.S. patents, for a 9-year term with automatic renewal.
- Also on August 1, 2022, NIKA signed a cooperation agreement with Nika BioTechnology, Inc. (OTCMKTS: NIKA) for joint development and cost sharing of prescription drugs and dietary supplements, with profit sharing equally divided for 15 years.
- On August 31, 2022, NIKA signed an exclusive rights agreement appointing it as exclusive representative for production and sale of six additional dietary supplements across multiple continents.
- On October 11, 2022, NIKA acquired a 40% stake in Nika Europe, Ltd., which is preparing to build a pharmaceutical factory with capacity for various drug forms.
- On February 12, 2024, NIKA merged with Nika BioTechnology, Inc., increasing its controlling interest in Nika Europe, Ltd. to 80%.
- The merger was accounted as a common control merger with assets and liabilities recorded at carry-over basis.
- On January 25, 2024, NIKA's common stock was listed on OTC Markets PINK under symbol NKPH, later changed to NIKA on May 6, 2024.
- On December 9, 2024, NIKA's common stock was uplisted to OTCQB where it currently trades.
- NIKA qualifies as an emerging growth company and avails exemptions from certain disclosure and accounting requirements.
- As of December 31, 2025, NIKA had not adopted formal insider trading policies but relies on general securities laws.
- NIKA operates with two executive officers: CEO/CFO Dimitar Slavchev Savov and Corporate Secretary Clifford P. Redekop.
- There are no material legal proceedings pending or threatened against NIKA or its officers.
- Financial snapshot as of September 30, 2026, shows cash and equivalents of $352,000, current assets of $5.309 million, current liabilities of $349.014 million, resulting in a current ratio of 0.02 and cash ratio of 0.
- Net income for the nine months ended September 30, 2026, was a loss of $13.023 million.
- Revenue reported for fiscal year 2024 was zero.
- Basic and diluted earnings per share for the nine months ended September 30, 2026, were zero.
- The company has a very low liquidity position with current liabilities vastly exceeding current assets.
- Recent news items do not directly mention NIKA but include industry and market context relevant to pharmaceuticals and biotech sectors.
Generated 2026-11-10
- S1 | 2026-03-25 | 10-K
- S2 | 2026-11-10 | 10-Q
- N1 | 2026-11-10 | www.nasdaq.com | Chevron Is Doubling Venezuela Production. ExxonMobil Says It's Not in a Rush. Who's Right? | https://www.nasdaq.com/articles/chevron-doubling-venezuela-production-exxonmobil-says-its-not-rush-whos-right
- N2 | 2026-11-10 | www.nasdaq.com | Mirum Pharmaceuticals' Brelovitug Meets Primary Endpoint In Phase 3 AZURE-4 Study | https://www.nasdaq.com/articles/mirum-pharmaceuticals-brelovitug-meets-primary-endpoint-phase-3-azure-4-study
- N3 | 2026-11-10 | www.nasdaq.com | CMC CFO Paul Lawrence To Retire, Kenji Hashimoto Named Successor | https://www.nasdaq.com/articles/cmc-cfo-paul-lawrence-retire-kenji-hashimoto-named-successor
- N4 | 2026-08-10 | www.nasdaq.com | Cotton Extending Gains to Monday Morning | https://www.nasdaq.com/articles/cotton-extending-gains-monday-morning-0
- N5 | 2026-08-10 | www.nasdaq.com | Soybeans Holding onto Gains at Midday | https://www.nasdaq.com/articles/soybeans-holding-gains-midday-1
- N6 | 2026-08-10 | www.nasdaq.com | Can Palantir Reach $207 per Share to Claim a New All-Time High Before 2026 Is Over? | https://www.nasdaq.com/articles/can-palantir-reach-207-share-claim-new-all-time-high-2026-over
- N7 | 2026-08-10 | www.nasdaq.com | Cotton Extending Gains to Monday Morning | https://www.nasdaq.com/articles/cotton-extending-gains-monday-morning
- N8 | 2026-08-10 | www.nasdaq.com | Cathie Wood's ARK Bought $40 Million of Nvidia, Tesla, and SpaceX During Last Month's AI Sell-Off. Was She Right to Buy the Dip? | https://www.nasdaq.com/articles/cathie-woods-ark-bought-40-million-nvidia-tesla-and-spacex-during-last-months-ai-sell-was
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


